Modified BCL9 mimetic peptides

Abstract

Provided are BCL9-mimetic peptides having a modified α-helical homology domain-2 (HD2) region and optionally having a cell membrane-permeable region, compositions comprising the BCL9-mimetic peptides, and methods of using the BCL9-mimetic peptides to inhibit proliferation and / or promote cytotoxicity in neoplastic cells.

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority to U.S. Provisional Patent Application No. 62 / 870,938, filed July 5, 2019.

[0002] Sequence Listing This application contains a Sequence Listing that has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. The ASCII copy was created on July 6, 2020, is named Sapience_004_WO1_SL.txt, and is 49,081 bytes in size. [Background technology]

[0003] B-cell CLL / lymphoma 9 (BCL9) is a protein that acts as a coactivator for β-catenin-mediated transcription. BCL9 is overexpressed in many tumors and enhances β-catenin signaling in cancer cells but not in the normal cells that give rise to the tumor (Zhan et al. 2017). BCL9 interacts with β-catenin through its α-helical homology domain-2 (HD2). Previous studies have shown that disrupting the BCL9 / β-catenin interaction using hydrocarbon-stapled BCL9 peptides suppresses the transcription of Wnt target genes that regulate the proliferation, migration, invasiveness, and metastatic potential of tumor cells (Takada et al., 2012, WO2017 / 062518). Summary of the Invention

[0004] Some of the main aspects of the present invention are summarized below. Further aspects are described in the detailed description, examples, drawings and claims sections of this disclosure. The description in each section of this disclosure is intended to be read in conjunction with the other sections. Furthermore, the various embodiments described in each section of this disclosure can be combined in various ways, and all such combinations are intended to be included in the scope of the present invention.

[0005] The present invention provides BCL9 mimetic peptides that contain a modified BCL9 α-helical homology domain-2 (HD2) region. In one embodiment, the invention provides a BCL9 mimetic peptide comprising a modified BCL9 α-helical homology domain-2 (HD2) region, wherein the modified BCL9 HD2 region comprises a variant of the amino acid sequence LSQEQLEHRERSLQTLRDIQRMLF (SEQ ID NO: 1), wherein the variant has the following modifications at one or more positions of SEQ ID NO: 1: (i) E7 is replaced with R; (ii) R11 is replaced with E; (iii) S12 is replaced with A; (iv) Q14 is replaced with A or E; (v) T15 is replaced with A; (vi) D18 is replaced with A or R; (vii) I19 is replaced with L; (viii) R21 is replaced with E; (ix) M22 is replaced with A or L; (x) W, 1-Nal or 2-Nal is added at position 25. The BCL9 mimetic peptide may further comprise the modification of replacing F24 with W, 1-Nal or 2-Nal, and / or truncating 1-15 contiguous amino acids starting from L1 of SEQ ID NO: 1. In one embodiment, the modified BCL9 HD2 region comprises an amino acid sequence selected from the group consisting of LSQEQLEHRERSLATLRAIQRMLF (SEQ ID NO: 3), LSQEQLRHREESLETLRRIQEMLF (SEQ ID NO: 4), LSQEQLEHRERALQALRAIQRALF (SEQ ID NO: 5), and ALQALRAIQRALF (SEQ ID NO: 6). Also included are retro-inverso BCL9 mimetic peptides that comprise D-amino acids in a reversed amino acid sequence compared to the amino acid sequences disclosed herein.

[0006] One embodiment of the present invention is a BCL9 mimetic peptide comprising a modified BCL9 α-helical homology domain-2 (HD2) region, wherein the modified BCL9 HD2 region is a D-amino acid sequence comprising a variant of the D-amino acid sequence FLMRQIDRLTQLS (SEQ ID NO:7), wherein the variant has the following modifications at one or more positions of SEQ ID NO:7: (i) F1 is replaced with L or W; (ii) M3 is replaced with A, E, L or V; (iii) R4 is replaced with O (ornithine); (iv) I6 is replaced with L; (v) D7 is replaced with A or E; (vi) R8 is replaced with A; (vii) T10 is replaced with A, K, Q or R; (viii) Q11 is replaced with A, K or R; or (ix) S13 is replaced with A. In certain embodiments, the BCL9 mimetic peptide further comprises W, F, R, 1-Nal or 2-Nal, in either the D- or L-form, at the N-terminus of the peptide.

[0007] In an embodiment, the modified BCL9 HD2 region is selected from the group consisting of FLMRQIDRLTQLA (SEQ ID NO: 8), FLMRQLDRLTQLA (SEQ ID NO: 9), FLARQLARLAQLA (SEQ ID NO: 10), WLARQLARLAQLA (SEQ ID NO: 11), WWLARQLARLAQLA (SEQ ID NO: 12), FLMEQLRRLTELA (SEQ ID NO: 13), FLAEQLRRLAELA (SEQ ID NO: 14), WLAEQLRRLAELA (SEQ ID NO: 15), WWLARQLERLAQLA (SEQ ID NO: 16), 1-Nal-WLARQLARLRQLA (SEQ ID NO: 17), FLLRQIDRLTQLA (SEQ ID NO: 18), FLLRQLDRLTQLA (SEQ ID NO: 19), FLLRQLERLTQLA (SEQ ID NO: 20), WWLLRQLARLAQLA (SEQ ID NO: 102), 2-Nal-WLA The D-amino acid sequence is selected from the group consisting of RQLARLAQLA (SEQ ID NO:115), FWLARQLARLAQLA (SEQ ID NO:116), WWLARQLARLRQLA (SEQ ID NO:117), WFLARQLARLAQLA (SEQ ID NO:118), WLLARQLARLAQLA (SEQ ID NO:119), WWLERQLARLAQLA (SEQ ID NO:120), WWLARQLARLQQLA (SEQ ID NO:122), WWLARQLERLARLA (SEQ ID NO:123), WWLARQLERLRRLA (SEQ ID NO:124), WWLARQLARLKQLA (SEQ ID NO:125), WWLARQLERLAKLA (SEQ ID NO:126), WWLVRQLARLAQLA (SEQ ID NO:127) and WWLAOQLAOLAQLA (SEQ ID NO:140).

[0008] In certain embodiments, the BCL9 mimetic peptides of the present invention comprise a modified BCL9 α-helical homology domain-2 (HD2) region that is chiral. In certain embodiments, the modified BCL9 HD2 region comprises: (i) F D R L [WLARQLARLAQLA] D (SEQ ID NO: 103), (ii) F D R L [WLVRQLARLAQLA] D (SEQ ID NO: 104), (iii) F D W L[WLVRQLARLAQLA] D (SEQ ID NO: 105), (iv) F D W L [WLARQLARLAALA] D (SEQ ID NO: 106), (v) F D W L [WLARQLAALAQLA] D (SEQ ID NO: 107), (vi) W L -[WLARQLARLAQLA] D (SEQ ID NO: 108), (vii) W L -[WLARQLARLRQLA] D (SEQ ID NO: 109), (viii) W L -[WLARQLERLRRLA] D (SEQ ID NO: 110), (ix) W L -[WLARQLERLARLA] D (SEQ ID NO: 111), (x) F L -[WLARQLARLAQLA] D (SEQ ID NO: 112), (xi) R L -[WLARQLARLAQLA] D (SEQ ID NO: 113), (xii) F D -W L -[WLARQLARLAQLA] D (SEQ ID NO: 114), and W L -[WLVRQLARLAQLA] D (SEQ ID NO:141), where the subscripts D and L represent the chirality of the amino acid.

[0009] In some embodiments, the BCL9 mimetic peptide comprises a cell membrane permeable region, and the BCL9 mimetic peptide is a cell membrane permeable peptide. In some embodiments, the cell membrane permeable region has an amino acid sequence selected from the group consisting of YGRKKRRQRRR (SEQ ID NO: 61) and VPTLK (SEQ ID NO: 32), or the cell membrane permeable region has a D-amino acid sequence selected from the group consisting of RRRQRRKKRGY (SEQ ID NO: 73), KLTPV (SEQ ID NO: 74), PSDGRG (SEQ ID NO: 75), and OLTPV (SEQ ID NO: 143).

[0010] In some embodiments, the BCL9 mimetic peptide comprises an N-terminal group selected from the group consisting of acetyl, naphthyl, octanoyl, phenyl, and isovaleryl, and / or the BCL9 mimetic peptide comprises a C-terminal amide group.

[0011] In one aspect, the BCL9 mimetic peptides of the present invention are for use in inhibiting proliferation and / or promoting cytotoxicity in neoplastic cells.

[0012] Further aspects of the invention provide compositions, such as pharmaceutical compositions, that comprise the BCL9-mimetic peptides of the invention; kits that comprise the BCL9-mimetic peptides of the invention; and nucleic acid molecules that encode the BCL9-mimetic peptides of the invention.

[0013] The present invention further provides a method of inhibiting proliferation and / or promoting cytotoxicity in a neoplastic cell comprising contacting the neoplastic cell with a BCL9-mimetic peptide of the present invention. [Brief description of the drawings]

[0014] [Figure 1] FIG. 1 shows that modified BCL9 mimetic peptides of the invention antagonize β-catenin and exert anti-proliferative activity in cultured MCF7 breast cancer cells. [Figure 2A] Figure 2 shows that retro-inverso BCL9 mimetic peptides of the invention exhibit anti-proliferative activity in cultured MCF7 breast cancer cells. Cytotoxicity data for peptide BCL-26 (Figure 2A) and peptide BCL-27 (Figure 2B) are shown. [Figure 2B] Figure 2 shows that retro-inverso BCL9 mimetic peptides of the invention exhibit anti-proliferative activity in cultured MCF7 breast cancer cells. Cytotoxicity data for peptide BCL-26 (Figure 2A) and peptide BCL-27 (Figure 2B) are shown. [Figure 3A]Figure 3 shows that the retro-inverso BCL9 mimetic peptide of the present invention exhibits antitumor activity in MCF7 breast cancer mouse model. Data points represent mean ± SEM. Nude mice were administered BCL-26 (12.5 mg / kg) on ​​day 2 after tumor inoculation (Figure 3A, p<0.0001). [Figure 3B] Figure 3 shows that the retro-inverso BCL9 mimetic peptide of the present invention exhibits antitumor activity in MCF7 breast cancer mouse model. Data points represent mean ± SEM. BCL-87 (5 mg / kg) was administered 21 days after tumor inoculation (Figure 3B, p<0.005). [Figure 3C] Figure 3 shows that the retro-inverso BCL9 mimetic peptides of the present invention exhibit antitumor activity in a MCF7 breast cancer mouse model. Data points represent the mean ± SEM. Two concentrations (1 mg / kg and 5 mg / kg) of BCL-87 and BCL-27 were administered 14 days after tumor inoculation (Figure 3C, p < 0.0004 vs. control for all tested peptides). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0015] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of pharmacology, formulation science, protein chemistry, cell biology, cell culture, molecular biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art.

[0016] In order that the present invention may be more readily understood, some terms are first defined. Further definitions are provided throughout this disclosure. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which this invention pertains.

[0017] Any headings provided herein are not limitations of the various aspects or embodiments of the invention that can be made by reference to the specification as a whole, and therefore the terms defined immediately below are more fully defined by reference to the specification in its entirety.

[0018] All references cited in this disclosure are hereby incorporated by reference in their entirety. Additionally, any manufacturer's manual or catalog for any product cited or referred to herein is incorporated by reference. Any document incorporated by reference herein, or any teaching therein, may be used in the practice of the present invention. Documents incorporated by reference herein are not admitted to be prior art.

[0019] I. Definition The phrases or terminology in this disclosure are intended to be descriptive and not limiting, as the terminology or terminology herein would be interpreted in light of the teachings and guidance of one of ordinary skill in the art.

[0020] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include the plural references unless the context clearly indicates otherwise. The term "a" (or "an"), as well as the terms "one or more" and "at least one," can be used interchangeably.

[0021] Furthermore, "and / or" should be considered to specifically disclose each of the two specified features or components with or without the other. Thus, the term "and / or" used in a phrase such as "A and / or B" is intended to include A and B, A or B, A (alone), and B (alone). Similarly, the term "and / or" used in the phrase "A, B and / or C" is intended to include A, B and C; A, B or C; A or B; A or C; B or C; A and B; A and C; B and C; A (alone); B (alone); and C (alone).

[0022] Wherever an embodiment is described using the word "comprising," other similar embodiments described using the words "consisting of" and / or "consisting essentially of" are included.

[0023] Units, prefixes, and symbols are expressed in their International System of Units (SI) approved format. Numerical ranges include the numbers defining the range, and any individual value provided herein can serve as an endpoint of a range that includes other individual values ​​provided herein. For example, a set of values, e.g., 1, 2, 3, 8, 9, and 10, is also a disclosure of numerical ranges from 1 to 10, 1 to 8, 3 to 9, etc. Similarly, a disclosed range is a disclosure of each individual value encompassed in the range. For example, the specified range of 5 to 10 is also a disclosure of 5, 6, 7, 8, 9, and 10.

[0024] The terms "polypeptide", "peptide" and "protein" are used interchangeably herein to refer to polymers of amino acids of any length. Polymers may be linear or branched, may contain modified amino acids, and may be interrupted by non-amino acids. Unless otherwise indicated, three-letter and one-letter abbreviations as used in the art are used herein to represent amino acid residues, e.g., for the abbreviations for uncommon or unnatural amino acids set forth herein. Amino acids are L-amino acids unless preceded by a "D" or in lower case. Groups or strings of amino acid abbreviations are used to represent peptides. Except where specifically indicated, peptides are shown with the N-terminus at the left and sequences are written from the N-terminus to the C-terminus.

[0025] Polypeptides, peptides and proteins may include natural or synthetic modifications, such as disulfide bonds, lactam bridges, glycosylation, lipidation, acetylation, acylation, amidation, phosphorylation, or other manipulations or modifications, such as conjugation with a labeling component or addition of a protecting group. Also included are, for example, polypeptides containing one or more analogs of amino acids, including, for example, amino-isobutyric acid (Aib), unnatural amino acids, such as naphthylalanine (Nal), and the like, as well as polypeptides that comprise or consist of D-amino acids and other modifications known in the art. Polypeptides may be in one or more salt forms. Preferred salt forms include acetate, chloride or trifluoroacetate. In certain embodiments, polypeptides may exist as single chains, covalently linked dimers or non-covalently associated chains. Polypeptides may be in cyclic form. Cyclic polypeptides may be prepared, for example, by crosslinking free amino acids with free carboxyl groups. Formation of the cyclic compound may be accomplished by treatment with a dehydrating agent, with appropriate protection if necessary. The reaction from open chain (linear form) to cyclic form can involve intramolecular cyclization. Cyclic polypeptides can also be prepared by other methods known in the art, such as using one or more lactam bridges, hydrogen bond surrogates (Patgiri et al. 2008), hydrocarbon staples (Schafmeister et al. 2000), triazole staples (Le Chevalier Isaad et al. 2009), or disulfide bridges (Wang et al. 2006). The distance separating the bridges or staples can be, for example, 3, 4, 7, or 8 amino acids.

[0026] The term "variant" refers to a polypeptide having one or more amino acid substitutions, deletions and / or insertions compared to a reference sequence. Deletions and insertions can be internal and / or at one or more termini. Substitutions can include replacement of one or more amino acids with similar or homologous amino acid(s) or non-similar amino acid(s). For example, some variants include alanine substitutions at one or more amino acid positions. Other substitutions include conservative substitutions that have little or no effect on the overall net charge, polarity or hydrophobicity of the protein. Some variants include non-conservative substitutions that change the charge or polarity of the amino acid. Substitutions can be with either L- or D-form amino acids.

[0027] "Retro-inverso" polypeptides have an inverted amino acid sequence compared to the naturally occurring L-amino acid sequence and are composed of D-amino acids (the alpha-center chirality of the amino acid subunits is inverted), thereby helping to maintain a side chain topology similar to that of native L-amino acid peptides.

[0028] The term "conservative substitution" as used herein refers to the replacement of one or more amino acids with another biologically similar residue. Examples include the replacement of amino acid residues with similar properties, such as small amino acids, acidic amino acids, polar amino acids, basic amino acids, hydrophobic amino acids and aromatic amino acids. For more information on phenotypically silent substitutions in peptides and proteins, see, for example, Bowie et.al., Science 247:1306-1310 (1990). In the following table, conservative substitutions of amino acids are classified according to physicochemical properties, where I is neutral and / or hydrophilic, II is acid and amide, III is basic, IV is hydrophobic, and V is aromatic bulky amino acid. [Table 1]

[0029] In the table below, conservative amino acid substitutions are classified by physicochemical properties: VI is neutral or hydrophobic, VII is acidic, VIII is basic, IX is polar, and X is aromatic. [Table 2]

[0030] Methods for identifying conservative nucleotide and amino acid substitutions that do not affect protein function are well known in the art (see, e.g., Brummell et al., Biochem. 32:1180-1187 (1993); Kobayashi et al., Protein Eng. 12(10):879-884 (1999); and Burks et al., Proc. Natl. Acad. Sci. USA 94:412-417 (1997)).

[0031] The term "identical" or percent "identity" with respect to two or more nucleic acids or polypeptides means that two or more sequences or subsequences are the same or have a specified percentage of the same nucleotides or amino acid residues when compared and aligned (introducing gaps, if necessary) to obtain maximum correspondence without considering any conservative amino acid substitutions as part of the sequence identity. Percent identity can be measured using sequence comparison software or algorithms or by visual inspection. Various algorithms and software that can be used to obtain alignment of amino acid or nucleotide sequences are known in the art.

[0032] One such non-limiting example of a sequence alignment algorithm is described in Karlin et al., Proc. Natl. Acad. Sci., 87:2264-2268 (1990), which was modified in Karlin et al., Proc. Natl. Acad. Sci., 90:5873-5877 (1993), and incorporated into the NBLAST and XBLAST programs (Altschul et al., Nucleic Acids Res., 25:3389-3402 (1991)). In one embodiment, Gapped BLAST, as described in Altschul et al., Nucleic Acids Res. 25:3389-3402 (1997), may be used. BLAST-2, WU-BLAST-2 (Altschul et al., Methods in Enzymology, 266:460-480 (1996)), ALIGN, ALIGN-2 (Genentech, South San Francisco, California) or Megalign (DNASTAR) are other publicly available software programs that can be used to align sequences. In one embodiment, the percent identity of two nucleotide sequences is determined using the GAP program in the GCG software package (e.g., using the NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70 or 90, and a length weight of 1, 2, 3, 4, 5 or 6). In an alternative embodiment, the percent identity of two amino acid sequences can be determined using the GAP program in the GCG software package incorporating the algorithm of Needleman and Wunsch (J. Mol. Biol. (48): 444-453 (1970)) (e.g., using either the BLOSUM 62 matrix or the PAM250 matrix, and gap weights of 16, 14, 12, 10, 8, 6 or 4, and length weights of 1, 2, 3, 4, 5). Alternatively, in an embodiment, the percent identity of nucleotide or amino acid sequences is determined using the algorithm of Myers and Miller (CABIOS 4: 11-17 (1989)).For example, percent identity can be determined using the ALIGN program (version 2.0) and using PAM120 as a residue table, a gap length penalty of 12, and a gap penalty of 4. Those skilled in the art can determine appropriate parameters for maximal alignment with a particular alignment software. In one embodiment, the default parameters of the alignment software are used. Other means for calculating identity include those described in Computational Molecular Biology (Lesk ed., 1988), Biocomputing: Informatics and Genome Projects (Smith ed., 1993), Computer Analysis of Sequence Data, Part 1 (Griffin and Griffin eds., 1994), Sequence Analysis in Molecular Biology (G. von Heinje, 1987), Sequence Analysis Primer (Gribskov et al. eds., 1991), and Carillo et al., SIAM J. Applied Math., 48:1073 (1988).

[0033] As used herein, a "polynucleotide" may contain one or more "nucleic acids," "nucleic acid molecules," or "nucleic acid sequences," and refers to a polymer of nucleotides of any length, including DNA and RNA. A polynucleotide may be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases, and / or their analogs, or any substrate that can be incorporated into a polymer by DNA or RNA polymerase. A polynucleotide may contain modified nucleotides, such as methylated nucleotides and their analogs. The above applies to any polynucleotide referred to herein, including RNA and DNA.

[0034] An "isolated" molecule is one that is in a form not found in nature, including purified forms.

[0035] A "label" is a detectable compound that can be directly or indirectly conjugated to a molecule to produce a "labeled" molecule. The label can be itself detectable (e.g., radioisotope labels or fluorescent labels) or can be indirectly detected, such as by catalyzing a detectable chemical change of a substrate compound or composition (e.g., enzyme labels) or by other indirect detection means (e.g., biotinylation).

[0036] "Binding affinity" generally refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule and its binding partner (e.g., a receptor and its ligand, an antibody and its antigen, two monomers forming a dimer, etc.). Unless otherwise indicated, "binding affinity," as used herein, refers to the intrinsic binding affinity that reflects a 1:1 interaction between members of a binding pair. The affinity of a molecule X for its partner Y is often measured by the dissociation constant (K D ) Affinity can be measured by common methods known in the art, including those described herein. Low affinity binding partners tend to bind slowly and dissociate quickly, whereas high affinity binding partners tend to bind more quickly and remain bound for longer.

[0037] The affinity or avidity of a molecule for its binding partner can be determined experimentally using any suitable method known in the art, such as flow cytometry, enzyme-linked immunosorbent assay (ELISA), or radioimmunoassay (RIA), or kinetics (e.g., KINEXA® or BIACORE™ or OCTET® analysis). Direct binding assay and competitive binding assay formats can be readily adapted. (See, e.g., Berzofsky et al., “Antibody-Antigen Interactions,” In Fundamental Immunology, Paul, WE, ed., Raven Press: New York, NY (1984); Kuby, Immunology, WH Freeman and Company: New York, NY (1992)). The measured affinity of a particular binding pair interaction can vary when measured under different conditions (e.g., salt concentration, pH, temperature). Thus, affinity and other binding parameters (e.g., K D or Kd, K on , K off Measurements of ) are performed using standards of binding partner and standard buffers, as known in the art.

[0038] An "active agent" is a component intended to provide a biological activity. An active agent may be in association with one or more other components. An active agent that is a peptide may also be referred to as an "active peptide."

[0039] An "effective amount" of an active agent is an amount sufficient to carry out a specifically stated purpose.

[0040] The term "pharmaceutical composition" refers to a formulation that is in a form that allows the biological activity of the active ingredient to be effective and does not contain any additional ingredients that have unacceptable toxicity to the subject to which the composition will be administered. Such compositions may be sterile and may contain a pharma-ceutically acceptable carrier, such as saline. Suitable pharmaceutical compositions may include one or more of a buffer (e.g., acetate, phosphate, or citrate buffer), a surfactant (e.g., polysorbate), a stabilizer (e.g., polyol or amino acid), a preservative (e.g., sodium benzoate), and / or other commonly used solubilizing or dispersing agents.

[0041] The terms "inhibit," "block," and "suppress" are used interchangeably and refer to any statistically significant decrease in occurrence or activity, including completely blocking occurrence or activity. For example, "inhibition" can refer to about a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% decrease in activity or occurrence. An "inhibitor" is a molecule, factor, or substance that results in a statistically significant decrease in the occurrence or activity of a process, pathway, or molecule.

[0042] A "neoplastic cell" or "neoplasm" is typically one that has undergone some form of mutation / transformation resulting in abnormal growth compared to normal cells or tissues of the same type. Neoplasms include morphological irregularities and pathological growth. Neoplastic cells can be benign or malignant. Malignant neoplasms, or cancers, are distinguished from benign in that they exhibit loss of cellular differentiation and orientation and have properties of invasion and metastasis.

[0043] II. BCL9 MIMICKING PEPTIDES AND COMPOSITIONS BCL9 Mimetic Peptides BCL9 is a 149 kDa eukaryotic protein involved in signal transduction through the Wnt pathway. BCL9 binds to β-catenin and promotes its transcriptional activity. The β-catenin binding region or "HD2 domain" of BCL9 is a 24-residue α-helix located at amino acids 351-374 of BCL9 (SEQ ID NO: 1). The complete amino acid sequence of wild-type human BCL9 is shown in NCBI Accession No. NP_004317.2.

[0044] Peptide ST-BC1 (SEQ ID NO:2) is a cyclic variant of the native BCL9 HD2 domain with a lactam bridge between residues 14 and 18. Previous studies have shown that analogs of ST-BC1 with a hydrocarbon bridge between residues 14 and 18 inhibit Wnt transcriptional activity in human colon carcinoma cells and exhibit antitumor activity in mouse models (Takada et al. 2012). The inventors have discovered that non-conservative linear variants of ST-BC1 induce cell death in neoplastic cells and reduce tumor volume in animal models. The discovery that the BCL9-derived peptides of the present invention have multiple non-conservative amino acid substitutions relative to the wild-type BCL9 HD2 region yet retain the ability to specifically target and kill neoplastic cells was unpredictable prior to the present invention. Moreover, the retro-inverso variants were not only active but also had comparable activity compared to ST-BC1 and the linear "L" variant, which was also unpredictable.

[0045] The present invention provides BCL9 mimetic peptides having a modified BCL9 HD2 region and optionally a cell membrane permeable region. The BCL9 peptides of the present invention are "mimetics" in the sense that they can interfere with or inhibit wild-type BCL9 activity in cells into which they are introduced. More specifically, the BCL9 mimetic peptides of the present invention can bind to β-catenin and compete with the binding of native BCL9 to β-catenin. In some embodiments, the BCL9 mimetic peptides can downregulate the expression of one or more members of the Wnt signaling pathway, such as axin, CD44, c-Myc, cyclin D1, LEF1, LGR5, survivin, and VEGF-A. In some embodiments, the BCL9 mimetic peptides can inhibit cell proliferation, angiogenesis, and / or cell migration. BCL9 activity can be assessed by any of several assays known in the art (Kawamoto et al. 2009, WO2017 / 062518), including the cell killing assays described herein.

[0046] A "modified BCL9 HD2 region" is a sequence derived from a wild-type BCL9 HD2 region, which has at least one addition, deletion or substitution compared to the wild-type BCL9 HD2 sequence. The modified BCL9 HD2 region preferably comprises a peptide corresponding to at least positions 16-23 of SEQ ID NO: 1 and containing at least one addition, deletion or substitution compared to SEQ ID NO: 1. The modified BCL9 HD2 region may, for example, comprise an amino acid sequence as shown in Table 1. The native BCL9 HD2 sequence (SEQ ID NO: 1) is shown as a point of reference. Substitutions in SEQ ID NO: 1 are shown in bold and underlined. [Table 3]

[0047] The modified BCL9 HD2 region can be in a retro-inverso form, for example, having the D-amino acid sequence X1LX2X3QLX4X5LX6X7LA (SEQ ID NO: 142), where each amino acid at positions 1-13 is independently selected from those shown in Table 2. [Table 4]

[0048] In the D-amino acid HD2 domain sequences shown in Table 2, only one of positions 4 or 8 can be alanine, i.e., if position 4 is A then position 8 cannot be A and vice versa. The BCL9 HD2 region can optionally comprise a D- or L-amino acid at position-1 selected from the group consisting of F, 1-Nal, 2-Nal, R and W. Additionally, the BCL9 HD2 region can optionally comprise a D- or L-amino acid at position-2 selected from the group consisting of F, 1-Nal, 2-Nal and W. In one embodiment, when position-1 is R, position 1 is F or W and / or position-2 is F, 1-Nal, 2-Nal or W.

[0049] Specific examples of retro-inverso BCL9 HD2 regions are shown in Table 3. The retro-inverso sequence of a portion of the wild-type BCL9 HD2 region (SEQ ID NO: 7) is shown as a point of reference. Substitutions in SEQ ID NO: 7 are shown in bold and underlined. [Table 5]

[0050] The modified BCL9 HD2 region may contain additional D-amino acids corresponding to the complete retro-inverso sequence of SEQ ID NO: 1. For example, the modified BCL9 HD2 region may contain the D-amino acid sequence [ka] where substitutions and additions to the retro-inverso wild-type BCL9 HD2 sequence are shown in bold and underlined.

[0051] The modified BCL9 HD2 region may contain amino acids of mixed chirality, such that one or more amino acids in the peptide are in the L-form and one or more amino acids are in the D-form. For example, an L-peptide may contain one or more D-amino acids. Similarly, a retro-inverso D-peptide may contain one or more L-amino acids. In one embodiment, the BCL9 HD2 region is [ka] where the subscripts D and L represent the chirality of the amino acids and substitutions and additions relative to the retro-inverso wild-type BCL9 HD2 sequence (SEQ ID NO:7) are shown in bold and underlined.

[0052] Variants of these sequences are also within the scope of the invention. The BCL9 mimetic peptides of the invention can have a HD2 region that is at least about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the sequences disclosed herein.

[0053] In embodiments where the BCL9 mimetic peptide comprises another active peptide, such as a cell membrane permeable region or an RGD-like sequence, the active peptide is operably linked to the modified BCL9 HD2 region. In some embodiments, the active peptide is covalently linked to the modified BCL9 HD2 region, such as by a peptide bond, a disulfide bond, a thioether bond, or a linker known in the art. Exemplary linkers include, but are not limited to, substituted alkyl, substituted cycloalkyl, polyethylene glycol, and derivatives thereof. The linker may be cleavable after the peptide is delivered into the cell. The active peptide and the modified BCL9 HD2 region may be directly linked by an amide bond, which may be referred to as a "fusion." The fusion may contain an amino acid linker sequence between the active peptide and the modified BCL9 HD2 region, as described above with respect to the active peptide. The active peptide may be linked to the N-terminus or C-terminus of the modified BCL9 HD2 region, or via a residue side chain. The active peptide and the modified BCL9 HD2 region may have the same or opposite chirality.

[0054] The cell membrane permeable BCL9 mimetic peptide of the present invention may comprise any combination of cell membrane permeable and modified BCL9 HD2 regions disclosed herein. Non-limiting examples of such peptides are shown in Table 4. The cell membrane permeable regions are italicized. Peptide BCL-21 comprises the native BCL9 HD2 sequence and is inefficient in inhibiting cell proliferation. Substitutions to the native BCL9 HD2 sequence are shown in bold and underlined. [Table 6]

[0055] Also included are retro-inverso forms of BCL9 mimetic peptides. Exemplary embodiments of cell membrane permeable retro-inverso BCL9 mimetic peptides are shown in Table 5. [Table 7]

[0056] The cell membrane permeable and RGD-like regions are in italics. Substitutions and additions to the retro-inverso wild-type BCL9 HD2 sequence (SEQ ID NO: 7) are shown in bold and underlined. The invention also includes peptides that include a BCL9 HD2 region shown in Table 5 and a different active peptide, such as a different cell membrane permeable region, and peptides that include a BCL9-HD2 region shown in Table 5 without an active peptide.

[0057] The BCL9 mimetic peptides of the present invention may contain amino acids of mixed chirality, such that one or more amino acids in the peptide are L-form and one or more amino acids are D-form. Non-limiting examples of BCL9 mimetic peptides with mixed chirality are shown in Table 6. [Table 8]

[0058] The subscripts D and L represent the chirality of the amino acids. The cell membrane permeable region is in italics. Substitutions and additions to the retro-inverso wild-type BCL9 HD2 sequence (SEQ ID NO: 7) are shown in bold and underlined. The invention also includes peptides that include the BCL9 HD2 region shown in Table 6 and a different active peptide, e.g., a different cell membrane permeable region, and peptides that include the BCL9-HD2 region shown in Table 6 without the active peptide.

[0059] BCL9 mimetic peptides of the present invention include peptides having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to a sequence disclosed herein.

[0060] The length of the BCL9 mimetic peptides of the present invention is preferably 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50 amino acids, and includes a range having any of these lengths as an endpoint, for example, 13 to 35 amino acids.

[0061] The BCL9 mimetic peptides may have a modified N-terminus and / or a modified C-terminus. For example, the BCL9 mimetic peptides may optionally include an N-terminal acetyl group and / or a C-terminal amide group. Other examples of optional N- and / or C-terminal groups include hydrophobic groups, such as linear or cyclic C2-C 18 Examples of the hydrophobic group include aliphatic or aromatic hydrocarbons, naphthyl, phenyl, octanoyl, and valeryl groups, including isovaleryl groups. In some embodiments, the BCL9 mimetic peptide comprises a linker or spacer between the peptide and the hydrophobic group. Examples of such linkers or spacers include aminohexanoic acid, beta-alanine, substituted alkyl, substituted cycloalkyl, and polyethylene glycol.

[0062] The BCL9 mimetic peptide of the present invention can be optionally cyclic. For example, the BCL9 mimetic peptide of the present invention can include one or more lactam bridges. Lactam bridges are preferably, but not necessarily, created between side chains spaced 3, 4, 7 or 8 amino acid residues apart (i.e., BxxB, BxxxB, BxxxxxxB, BxxxxxxxB). Lactam bridges can be formed, for example, between the side chains of Asp or Glu and Lys or Orn. ​​Amino acid substitutions can be made at the site of lactam bridges to facilitate linkage.

[0063] The BCL9 mimetic peptides of the present invention may optionally include one or more epitope and / or affinity tags for purification or detection, etc. Non-limiting examples of such tags include FLAG, HA, His, Myc, GST, etc. The BCL9 mimetic peptides of the present invention may optionally include one or more labels.

[0064] In certain embodiments, the present invention provides compositions, eg, pharmaceutical compositions, comprising a BCL9 mimetic peptide of the present invention, and optionally further comprising one or more carriers, diluents, excipients or other additives.

[0065] Also included within the scope of the present invention are kits that include the BCL9 mimetic peptides and compositions provided herein, and, optionally, instructions for use. The kits may further include at least one additional reagent and / or one or more additional active agents. The kits typically include a label indicating the intended use of the contents of the kit. In this regard, the term "label" includes any written or recorded material provided on or with the kit, or that otherwise accompanies the kit.

[0066] The BCL9 mimetic peptides of the invention can be used to inhibit proliferation and / or promote cytotoxicity in neoplastic cells. Proliferation and cytotoxicity can be measured by known assays, including the cell killing assays described herein.

[0067] Cell targeting The BCL9 mimetic peptides of the present invention can be introduced into target cells by methods known in the art. The method of introduction selected can depend, for example, on the intended use.

[0068] In some cases, the DNA or RNA encoding the BCL9 mimetic peptide is delivered to target cells and expressed therein.Depending on the application, delivery can be accomplished via any suitable vector.Examples of vectors include plasmids, cosmids, phages, bacteria, yeast, and engineered viral vectors, such as those derived from retroviruses, including lentiviruses, adenoviruses, adeno-associated viruses, and enveloped pseudotyped viruses.Vector can be introduced into cells, for example, using nanoparticles, hydrodynamic delivery, electroporation, sonoporation, calcium phosphate precipitation, or cationic polymers, such as DEAE-dextran.Vector can be complexed with lipids, for example encapsulated in liposomes, or associated with cationic condensing agents.

[0069] The BCL9 mimetic peptides of the present invention can be delivered to cells via mechanisms that utilize cell receptors. Examples of such mechanisms include antibody-drug conjugates, chimeric antigen receptors, multiple antigen presentation (MAP) systems, and integrin targeting, RGD-like sequences. Examples of RGD-like sequences include GRGDS (SEQ ID NO: 28) and GRGDNP (SEQ ID NO: 29). The BCL9 mimetic peptides of the present invention can include one or more RGD-like sequences, for example, two, three, four or five RGD-like sequences, linked as described herein or by any method known in the art. One or more RGD-like sequence(s) can be incorporated at the N-terminal or C-terminal side of the BCL9 HD2 region. Such RGD-like sequences can also be in retro-inverso form, independently of each other and the BCL9 HD2 region. One specific example of a retro-inverso RGD-like sequence is PSDGRG (SEQ ID NO: 75). Alternatively, BCL9 mimetic peptides can be encapsulated in vesicles, such as exosomes or liposomes, or micelles, and delivered to cells.Another method for introducing BCL9 mimetic peptides into cells is by cyclization, such as by using carbohydrate staples (Bernal et al. 2007, Bird et al. 2016), or other cyclization methods known in the art.

[0070] Certain BCL9 mimetic peptides of the present invention comprise a cell membrane permeable domain or cell membrane permeable peptide (CPP). The terms "cell membrane permeable domain", "cell membrane permeable region" and "cell membrane permeable peptide" are used interchangeably herein.

[0071] CPPs are short peptides (typically about 6-40 amino acids) that can cross cell membranes. Many CPPs can cross the blood-brain barrier (BBB). In some embodiments, the CPPs are 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, or 39 amino acids in length, including ranges having any of these lengths as endpoints, e.g., 10-30 amino acids. CPPs have the ability to transport covalently or non-covalently linked molecular cargo, e.g., polypeptides, polynucleotides, and nanoparticles, across cell membranes and the BBB. Translocation can be endocytic or energy-independent (e.g., non-endocytic) via translocation. Numerous CPPs have been described and characterized in the literature (see, for example, Handbook of Cell-Penetrating Peptides (2d ed. Ulo Langel ed., 2007), Herve et al. 2008, Heitz et al. 2009, Munyendo et al. 2012, Zou et al. 2013, Krautwald et al. 2016). A curated database of CPPs is maintained at crdd.osdd.net / raghava / cppsite (Gautam et al. 2012).

[0072] Peptides termed nuclear localization sequences (NLSs) are a subset of CPPs. Classical NLSs contain one (uni-) or two (binary) basic amino acid regions. The consensus sequences for classical uni- and binary NLSs are K(K / R)X(K / R) (SEQ ID NO: 30) and (K / R)(K / R)X, respectively.10-12 (K / R) 3 / 5 (SEQ ID NO: 31), where 3 / 5 represents at least 3 of 5 consecutive amino acids are lysine or arginine (Kosugi et al. 2009). The NLS sequence PKKKRKV (SEQ ID NO: 57) from SV40 large T antigen is an example of a classical unary NLS, while the NLS sequence KRPAATKKAGQAKKK (SEQ ID NO: 44) from nucleoplasmin is an example of a classical binary NLS (Lange et al. 2007, Kosugi et al. 2009). There are many non-classical NLSs, such as those from ribonucleoproteins (RNPs) hnRNP A1, hnRNP K, and U snRNP (Mattaj et al. 1998).

[0073] Non-limiting examples of CPPs suitable for use in the present invention include peptides derived from proteins, such as those derived from the Drosophila antennapedia transcription factor (penetratin and its derivatives RL-16 and EB1) (Derossi et al. 1998, Thoren et al. 2000, Lundberg et al. 2007, Alves et al. 2008), those derived from the HIV-1 transactivator of transcription (Tat) (Vives et al. 1997, Hallbrink et al. 2001), those derived from the rabies virus glycoprotein (RVG) (Kumar et al. 2007), those derived from herpes simplex virus VP22 (Elliott et al. 1997), those derived from antibacterial protegrin 1 (SynB) (Rousselle et al. 2001), those derived from the rat insulin 1 gene enhancer protein (pIS1) (Kilk et al. 2001, Magzoub et al. 2008), and those derived from the HIV-1 transactivator of transcription (Tat) (Vives et al. 1997, Hallbrink et al. 2001). al. 2001), mouse vascular endothelial cadherin (pVEC) (Elmquist et al. 2001), human calcitonin (hCT) (Schmidt et al. 1998), and fibroblast growth factor 4 (FGF4) (Jo et al. 2005).CPPs suitable for use in the present invention also include synthetic and chimeric peptides, such as transportan (TP) and its derivatives (Pooga et al. 1998; Soomets et al. 2000), membrane translocation sequences (MTS) (Brodsky et al. 1998; Lindgren et al. 2000; Zhao et al. 2001), such as MPS peptides (also known as fusion sequence based peptides or FBPs) (Chaloin et al. 1998), signal sequence based peptides (SBPs) (Chaloin et al. 1997), model amphipathic peptides (MAPs) (Oehlke et al. 1998; Scheller et al. 1999; Hallbrink et al. 2001), transit peptide 2 (TP2) (Cruz et al. 2013), MPG (Morris et al. 1997; Kwon et al. 2009), Pep-1 (Morris et al. 2009), and the like. al. 2001, Munoz-Morris et al. 2007), as well as polyarginines (e.g., R7-R. 12 (SEQ ID NO: 144) (Mitchell et al. 2000, Wender et al. 2000, Futaki et al. 2001, Suzuki et al. 2002). Representative sequences are shown in Table 7, but are not limited thereto. [Table 9-1] [Table 9-2]

[0074] Since the function of a CPP depends on its physical properties and not on sequence-specific interactions, it can have a reversed sequence and / or reversed chirality, such as those shown in Table 7 and / or known in the art. For example, retro-inverso forms of CPPs (reverse sequence and reversed chirality) are suitable for use in the present invention. Examples of retro-inverso CPPs include those having the D-amino acid sequences KKWKMRRNQFWIKIQR (SEQ ID NO: 71), KKWKMRRNQFWLKLQR (SEQ ID NO: 72), RRRQRRKKRGY (SEQ ID NO: 73), KLTPV (SEQ ID NO: 74) or OLTPV (SEQ ID NO: 143). Variants of these sequences with one or more amino acid additions, deletions and / or substitutions that retain the ability to cross cell membranes and / or the BBB are also suitable for use in the present invention. The BCL9 mimetic peptides of the present invention may comprise a cell membrane permeable domain having at least about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to the exemplary sequences shown in Table 7. The effect of amino acid addition(s), deletion(s) and / or substitution(s) on the ability of the CPP to mediate cell membrane permeation may be tested using methods known in the art.

[0075] III. Preparation method The BCL9 mimetic peptides of the invention can be chemically synthesized, for example, using solid phase or solution peptide synthesis, or expressed using recombinant methods. Synthesis or expression can also occur as fragments of the peptide, which are then subsequently linked together chemically or enzymatically.

[0076] Thus, also provided is a nucleic acid molecule encoding the BCL9 mimetic peptide of the present invention. Such a nucleic acid can be constructed by chemical synthesis using an oligonucleotide synthesis machine. The nucleic acid molecule of the present invention can be designed based on the amino acid sequence of the desired BCL9 mimetic peptide and the codon selection that will be favored in the host cell that will produce the recombinant BCL9 mimetic peptide. Standard methods can be applied to synthesize the nucleic acid molecule encoding the BCL9 mimetic peptide of interest.

[0077] Once prepared, the nucleic acid encoding a particular BCL9 mimetic peptide can be inserted into an expression vector and operably linked to expression control sequences suitable for expression of the peptide in a desired host. To obtain high levels of expression of the BCL9 mimetic peptide, the nucleic acid can be operably linked or associated with transcriptional and translational expression control sequences that function in the selected expression host.

[0078] A variety of expression host / vector combinations can be employed, any of which are known in the art. Useful expression vectors for eukaryotic hosts include, for example, vectors containing expression control sequences from SV40, bovine papilloma virus, adenovirus, and cytomegalovirus. Useful expression vectors for bacterial hosts include known bacterial plasmids, such as E. coli-derived plasmids, including pCR1, pBR322, pMB9, and their derivatives, broader host range plasmids such as M13, and filamentous single-stranded DNA phages.

[0079] Suitable host cells include prokaryotes, yeast, insects, or higher eukaryotic cells under the control of suitable promoters. Prokaryotes include gram-negative or gram-positive organisms, such as E. coli or bacilli. Higher eukaryotic cells can be established or cell lines derived from mammals, including Pichia pastoris, 293 cells, COS-7 cells, L cells, C127 cells, 3T3 cells, Chinese hamster ovary (CHO) cells, HeLa cells, and BHK cells. Cell-free transfer systems can also be employed. EXAMPLES

[0080] Embodiments of the present disclosure may be further defined by reference to the following non-limiting examples: It will be apparent to those skilled in the art that many modifications, both to materials and methods, may be practiced without departing from the scope of the disclosure.

[0081] Example 1. BCL9 peptides exhibit antiproliferative activity in cancer cells in vitro We generated a panel of peptides containing the cell membrane-permeable domain and the BCL9 HD2 domain and compared their activity with a previously described cyclic peptide, ST-BC1 (Takada et al. 2012). The BCL9 peptides described in this example are summarized in Table 8. [Table 10]

[0082] ST-BC1 contains a lactam bridge between the bold underlined residues. The other five peptides are linear with the TAT cell membrane permeable region shown in italics. Peptide BCL-21 contains the native HD2 domain, while peptides BCL-22-25 each have an amino acid substitution in the native BCL9 HD2 domain. Peptide BCL-25, in addition to the substitution, also has a shortened HD2 domain compared to the native sequence.

[0083] 2.5×10 496-well dishes containing MCF-7 breast cancer cells at a density of cells / well in 150 μL of MEM medium + 10% fetal bovine serum (FBS). Lyophilized BCL9 peptide was reconstituted in 270 mM trehalose buffer to a concentration of 10 mg / mL and a volume of 50 μL was added to each well to give a final concentration range of 2.5-40 μM. Cells were incubated with BCL9 peptide for 96 h at 37 °C.

[0084] Cell viability was quantified by spectrophotometry using the Roche MTT cell proliferation assay kit according to the manufacturer's instructions. Briefly, cells were washed with PBS and incubated for 4 hours at 37°C in fresh MEM medium containing 10% FBS, 1% penicillin / streptomycin, and 1% non-essential amino acids plus 10 μL of MTT reagent. After 4 hours, 100 μL of solubilization solution was added and cells were incubated overnight at 37°C with 5% carbon dioxide. Absorbance was measured at OD570nm with OD650nm as the reference. Absorbance is proportional to the number of viable cells. The percentage of absorbance relative to untreated control was quantified and expressed as % cell viability.

[0085] The modified BCL9 peptides of the invention, but not BCL-21, which has the native BCL9 HD2 domain sequence, demonstrated equal or greater antiproliferative activity in MCF7 breast cancer cells compared to peptide ST-BC1 (EC 50 In functional assays, EC 50 is the concentration that reduces a biological response by 50% of its maximum. For the BLC9 peptide, the EC 50 is measured as the concentration that reduces cell viability by 50% of its maximum value. 50 can be calculated by any number of means known in the art.

[0086] Example 2. Retro-inverso BCL9 peptides exhibit anti-proliferative activity in cancer cells in vitro We have prepared a retro-inverso peptide: D-amino acid sequence [ka] and BCL-26 having the D-amino acid sequence [ka] BCL-27 has the following structure: The cell membrane permeable region derived from the Bax inhibitor peptide is shown in italics. In BCL-26, the sequence of the HD2 domain is shortened by 11 amino acids and substituted at two positions compared to the native sequence. In BCL-27, the sequence of the HD2 domain is shortened by 11 amino acids and substituted at six positions compared to the native sequence, and contains an additional N-terminal tryptophan.

[0087] We investigated the cytotoxicity of peptides BCL-26 and BCL-27 using an assay in HL60 promyelocytic leukemia cells. HL60PML cells were suspended at a density of 3.5×10 in 150 μL of RPMI+1.5% fetal bovine serum (FBS) in a 96-well dish. 3 Cells / well were determined. BCL-26 or BCL-27, reconstituted at a concentration of 10 mg / mL in 20 mM His, pH 7.5, was added to each well in a volume of 50 μL to give a final concentration range of 0-80 μM. Cells were incubated with peptides for 48 hours at 37°C. Cell viability was quantified by flow cytometry using the Abcam Annexin V FITC Apoptosis Detection Kit. Briefly, cells were washed with PBS and resuspended in 1x assay buffer containing Annexin V FITC and propidium iodide (PI). Annexin V detects apoptotic cells and PI stains dead cells. After staining, apoptotic cells show green fluorescence, dead cells show red and green fluorescence, and live cells show little or no fluorescence. Cells were selected for analysis based on forward scatter (FSC) versus side scatter (SSC) and analyzed by a BD Accuri C6 Plus flow cytometer (Ex=488 nm, Em=530 nm) using a FITC signal detector to detect Annexin V-FITC binding, and PI staining was analyzed by a phycoerythrin luminescence signal detector.低 and P.I. 低 The percentage of viability was quantified and expressed as % viability. The retro-inverso peptides had similar activity to the standard peptides tested in Example 1 (FIGS. 2A-2B).

[0088] We investigated the cytotoxicity of additional retro-inverso and mixed chirality BCL9 mimetic peptides in HL60 cells using the above assay. The results are shown in Table 9. [Table 11-1] [Table 11-2]

[0089] The subscripts D and L represent the chirality of the amino acids. Substitutions and additions compared to the retro-inverso wild-type BCL9 HD2 sequence (SEQ ID NO: 7) are underlined and in bold. The cell membrane permeable and RGD-like regions are in italics. As expected, BCL-12 did not exhibit any cytotoxic activity due to the lack of a sequence for cell membrane permeability.

[0090] The lack of cytotoxic activity by BCL-134 indicates the requirement for a positively charged amino acid at at least one of position 4 or position 8 of the HD2 domain as compared to SEQ ID NO: 7. (Compare the activity of BCL-133 with the activity of BCL-134.)

[0091] The lack of cytotoxic activity by BCL-138 indicates the requirement that at least one of the two N-terminal amino acids of the HD2 domain be hydrophobic (compare the activity of BCL-91b with that of BCL-138).

[0092] Example 3. Retro-inverso BCL9 peptides exhibit antitumor activity in vivo In this experiment, we investigated the effect of peptide BCL-26 on tumor volume in a MCF7 subcutaneous tumor model. Briefly, 2 × 10 6 MCF7 breast cancer cells were implanted by subcutaneous injection into the axilla of NU / J mice. Peptide BCL-26 was administered by subcutaneous injection at a dose of 12.5 mg / kg, three times a week for three weeks. Dosing was administered 2 days after tumor inoculation, approximately 25 mm 3 Starting with a mean starting tumor volume of 100 mg / kg / day, the peptide BCL-26 significantly reduced tumor volume compared to vehicle (Figure 3A).

[0093] We also investigated the effect of the BCL9 mimetic peptide in established tumors. MCF7 cells were implanted in mice as described above. Peptide BCL-87 was administered by subcutaneous injection at a dose of 5 mg / kg, three times a week for three weeks. Dosing began 21 days after tumor inoculation, approximately 470 mm 3 Starting with a mean starting tumor volume of 100 mg / kg / day, the peptide BCL-87 significantly reduced tumor volume compared to vehicle (Figure 3B).

[0094] We further investigated the effect of different concentrations of mimetic peptides on established tumors. MCF7 cells were implanted in mice as described above. Peptides BCL-27 and BCL-87 were administered by subcutaneous injection at a dose of 1 mg / kg or 5 mg / kg, three times a week for three weeks. Dosing began 14 days after tumor inoculation, approximately 340 mm 3 Both peptides significantly reduced tumor volume compared to the vehicle and peptide control BCL-134 (Figure 3C). References Alves ID, et al. Membrane interaction and perturbation mechanisms induced by two cationic cell penetrating peptides with distinct charge distribution. Biochim. Biophys. Acta 1780:948-959 (2008). Bernal F,et al.Reactivation of the p53 Tumor Suppressor Pathway by a Stapled p53 Peptide.J.Am.Chem.Soc.129:2456-2457(2007)。 Bird GH,et al.Biophysical Determinants for Cellular Uptake of Hydrocarbon-Stapled Peptide Helices.Nat.Chem.Biol.12:845-852(2017)。 Brodsky JL,et al.Translocation of proteins across the endoplasmic reticulum membrane.Int.Rev.Cyt.178:277-328(1998)。 Chaloin L,et al.Conformations of primary amphipathic carrier peptides in membrane mimicking environments.Biochem.36:11179-11187(1997)。 Chaloin L,et al.Design of carrier peptide-oligonucleotide conjugates with rapid membrane translocation and nuclear localization properties.Biochem.Biophys.Res.Commun.243:601-608(1998)。 Cruz J,et al.A membrane-translocating peptide penetrates into bilayers without significant bilayer perturbations.Biophys.J.104:2419-2428(2013)。 Derossi D,et al.Trojan peptides:the penetratin system for intracellular delivery.Trends Cell Biol.8:84-87(1998)。 Elliott G,et al.Intercellular trafficking and protein delivery by a Herpesvirus structural protein.Cell 88:223-233(1997)。 Elmquist A,et al.VE-cadherin-derived cell-penetrating peptide,pVEC,with carrier functions.Exp.Cell Res.269:237-244(2001)。 Futaki S,et al.Arginine-rich peptides.An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery.J.Biol.Chem.276:5836-5840(2001)。 Gautam A,et al.CPPsite:a curated database of cell penetrating peptides.Database doi:10.1093 / database / bas015(2012)。 Hallbrink M,et al.Cargo delivery kinetics of cell-penetrating peptides.Biochim.Biophys.Acta 1515:101-109(2001)。 Heitz F,et al.Twenty years of cell-penetrating peptides:from molecular mechanisms to therapeutics.Brit.J.Pharmacol.157:195-206(2009)。 Herve F,et al.CNS delivery via adsorptive transcytosis.AAPS J.10:455-472(2008)。 Jo,D,et al.Intracellular protein therapy with SOCS3 inhibits inflammation and apoptosis.Nat.Med.11:892-898(2005)。 Kawamoto SA,et al.Analysis of the Interaction of BCL9 with β-Catenin and Development of Fluorescence Polarization and Surface Plasmon Resonance Binding Assays for this Interaction.Biochem.48:9534-9541(2009)。 Kilk K,et al.Cellular internalization of a cargo complex with a novel peptide derived from the third helix of the islet-1 homeodomain.Comparison with the penetratin peptide.Bioconjug.Chem.12:911-916(2001)。 Klein JS,et al.Design and characterization of structured protein linkers with differing flexibilities.Protein Eng.Des.Sel.27:325-330(2014)。 Kosugi S,et al.Six Classes of Nuclear Localization Signals Specific to Different Binding Grooves of Importin α.J.Biol.Chem.284:478-485(2009)。 Krautwald S,et al.Inhibition of regulated cell death by cell-penetrating peptides.Cell.Mol.Life Sci.73:2269-2284(2016)。 Kumar P,et al.Transvascular delivery of small interfering RNA to the central nervous system.Nature 448:39-43(2007)。 Kwon S-J,et al.Transduction of the MPG-tagged fusion protein into mammalian cells and oocytes depends on amiloride-sensitive endocytic pathway.BMC Biotechnol.9:73-84(2009)。 Lange A,et al.Classical Nuclear Localization Signals:Definition,Function,and Interaction with Importin α.J.Biol.Chem.282:5101-5105(2007)。 Le Chevalier Isaad A,et al.Side chain-to-side chain cyclization by click reaction.J.Pept.Sci.15:451-454(2009)。 Lindgren M,et al.Cell-penetrating peptides.Trends Pharmacol.Sci.21:99-103(2000)。 Lundberg P,et al.Delivery of short interfering RNA using endosomolytic cell-penetrating peptides.FASEB J.21:2664-2671(2007)。 Magzoub M,et al.Interaction and structure induction of cell-penetrating peptides in the presence of phospholipid vesicles.Biochim.Biophys.Acta 1512:77-89(2001)。 Mattaj IW,et al.Nucleocytoplasmic Transport:The Soluble Phase.Ann.Rev.Biochem.67:265-306(1998)。 Mitchell DJ,et al.Polyarginine enters cells more efficiently than other polycationic homopolymers.J.Pept.Res.56:318-325(2000)。 Morris MC,et al.A new peptide vector for efficient delivery of oligonucleotides into mammalian cells.Nucleic Acids Res.25:2730-2736(1997)。 Morris MC,et al.A peptide carrier for the delivery of biologically active proteins into mammalian cells.Nat.Biotechnol.19:1173-1176(2001)。 Munoz-Morris MA et al.The peptide carrier Pep-1 forms biologically efficient nanoparticle complexes.Biochem.Biophys.Res.Commun.355:877-882(2007)。 Munyendo WLL,et al.Cell penetrating peptides in the delivery of biopharmaceuticals.Biomolecules 2:187-202(2012)。 Oehlke J,et al.Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically.Biochim.Biophys.Acta 1414:127-139(1998)。 Patgiri A,et al.A hydrogen bond surrogate approach for stabilization of short peptide sequences in alpha helical conformation.Acc.Chem.Res.41:1289-1300(2008)。 Pooga M,et al.Cell penetration by transportan.FASEB J.12:67-77(1998)。 Rousselle C,et al.Enhanced delivery of doxorubicin into the brain via a peptide-vector-mediated strategy:saturation kinetics and specificity.J.Pharmacol.Exp.Ther.296:124-131(2001)。 Sampietro J,et al.Crystal Structure of a β-Catenin / BCL9 / Tcf4 Complex.Molec.Cell 24:293-300(2006)。 Schafmeister CE,et al.An All-Hydrocarbon Cross-Linking System for Enhancing the Helicity and Metabolic Stability of Peptides.J.Am.Chem.Soc.122:5891-5892(2000)。 Scheller A,et al.Structural requirements for cellular uptake of alpha-helical amphipathic peptides.J.Peptide Sci.5:185-194(1999)。 Schmidt MC,et al.Translocation of human calcitonin in respiratory nasal epithelium is associated with self assembly in lipid membrane.Biochem.37:16582-16590(1998)。 Soomets U,et al.Deletion analogues of transportan.Biochim.Biophys Acta 1467:165-176(2000)。 Suzuki T,et al.Possible existence of common internalization mechanisms among arginine-rich peptides.J.Biol.Chem.277:2437-2443(2002)。 Takada K,et al.Targeted Disruption of the BCL9 / β-catenin Complex Inhibits Oncogenic Wnt Signaling.Sci.Transl.Med.4:148ra117(2012)。 Thoren PEG,et al.The Antennapedia peptide penetratin translocates across lipid bilayers-the first direct observation.FEBS Lett.482:265-68(2000)。 Vives E, et al. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272:16010-16017 (1997). Wang XY, et al.Synthesis of small cyclic peptides containing the disulfide bond.ARKIVOC xi:148-154(2006). Wender PA, et al. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc. Natl. Acad. Sci. USA97:13003-13008 (2000). Zhan T, et al.Wnt signaling in cancer.Oncogene 36:1461-1473(2017). Zhao Y, et al.Chemical engineering of cell penetrating antibodies.J.Immunol.Methods 254:137-45(2001). Zou LL, et al. Cell-penetrating peptide-mediated therapeutic molecule delivery into the central nervous system. Curr. Neuropharmacol. 11:197-208 (2013). *** The invention is further described in the following claims.

Claims

1. 1. A BCL9 mimetic peptide comprising a modified BCL9 α-helical homology domain-2 (HD2) region, said modified BCL9 HD2 region being a D-amino acid sequence consisting of a variant of the D-amino acid sequence FLMRQIDRLTQLS (SEQ ID NO:7), said variant comprising at the following positions of SEQ ID NO:7: i. Replace F1 with W; ii. Replace M3 with L; iii. Replace I6 with L; iv. Substitute D7 for A; v. Replace T10 with A; vi. Substitute S13 with A; The following changes have been made: having the effect of promoting cytotoxicity in neoplastic cells; The BCL9 mimetic peptide.

2. 2. The BCL9 mimetic peptide of claim 1, further comprising a D-configuration of W at position -1 of SEQ ID NO:

7.

3. The BCL9 mimetic peptide of claim 1, further comprising a D-form of F at position -2 of SEQ ID NO:7, and a D-form of R at position -1 of SEQ ID NO:

7.

4. The BCL9-mimetic peptide according to any one of claims 1 to 3, further comprising a cell membrane-permeable domain, and wherein the BCL9-mimetic peptide is a cell membrane-permeable peptide.

5. The cell membrane permeable region has an amino acid sequence selected from the group consisting of YGRKKRRQRRR (SEQ ID NO:61) and VPTLK (SEQ ID NO:32); or The cell membrane permeable region has a D-amino acid sequence selected from the group consisting of RRRQRRKKRGY (SEQ ID NO: 73), KLTPV (SEQ ID NO: 74), PSDGRG (SEQ ID NO: 75) and OLTPV (SEQ ID NO: 143); The cell membrane-permeable BCL9 mimetic peptide according to claim 4.

6. The BCL9-mimetic peptide of any one of claims 1 to 5, wherein the peptide comprises an N-terminal group selected from the group consisting of acetyl, naphthyl, octanoyl, phenyl and isovaleryl.

7. The BCL9 mimetic peptide of any one of claims 1 to 6, wherein the peptide comprises a C-terminal amide group.

8. A composition comprising a BCL9 mimetic peptide according to any one of claims 1 to 7.

9. The composition of claim 8 which is a pharmaceutical composition.

10. A kit comprising a BCL9 mimetic peptide according to any one of claims 1 to 7 or a composition according to claim 8 or claim 9.

11. 1. An in vitro method for promoting cytotoxicity in neoplastic cells, comprising: Contacting said neoplastic cells with a BCL9 mimetic peptide according to any one of claims 1 to 7 or a composition according to claim 8 or claim 9. The method comprising:

12. 1. An in vitro method of inhibiting proliferation of neoplastic cells, comprising: Contacting said neoplastic cells with a BCL9 mimetic peptide according to any one of claims 1 to 7 or a composition according to claim 8 or claim 9. The method comprising:

13. A BCL9 mimetic peptide according to any one of claims 1 to 7 or a composition according to claim 8 or claim 9 for use in promoting cytotoxicity in neoplastic cells.

14. A BCL9 mimetic peptide according to any one of claims 1 to 7 or a composition according to claim 8 or claim 9 for use in inhibiting the proliferation of neoplastic cells.

15. Use of a BCL9 mimetic peptide according to any one of claims 1 to 7 or a composition according to claim 8 or claim 9 in the manufacture of a medicament for promoting cytotoxicity in neoplastic cells.

16. Use of a BCL9 mimetic peptide according to any one of claims 1 to 7 or a composition according to claim 8 or claim 9 in the manufacture of a medicament for inhibiting the proliferation of neoplastic cells.

Images